Treasury’s own guidance says its proposed COINS Act biotech rule does not list a standalone licence as covered. The final text will decide. Treasury released the proposal on 22 October 2026, and it would add biotechnology to the US outbound investment programme. The proposed definitions reach equity stakes, certain loans and joint ventures. Option and joint venture structures carry more risk.
Treasury’s fact sheet and FAQs set out the covered transactions. They are equity, certain debt financing, joint ventures, greenfield investments and certain limited partner stakes. Licensing is not named. Activities outside that definition fall outside the programme unless they are used to evade the rule.
What did Treasury propose on 22 October 2026?
Treasury issued a notice of proposed rulemaking on 22 October 2026. It implements the Comprehensive Outbound Investment National Security Act, known as the COINS Act. Congress passed the Act in the fiscal year 2026 National Defense Authorization Act, according to Treasury’s announcement.
The Act names five technology sectors. They are semiconductors and microelectronics, artificial intelligence, quantum information technologies, high-performance computing and hypersonic systems. Biotechnology is not among them. Treasury’s announcement says the Secretary has added it to the proposed regulations, using discretion the Act provides.
Treasury Secretary Scott Bessent said the department is “committed to putting America’s national security first.” Christopher Pilkerton is Assistant Secretary of the Treasury for Investment Security. He said the rules target “risks that can arise when foreign adversaries try to benefit” from US investment.
The proposal has no immediate legal effect, according to law firm Ropes & Gray. Comments are due on 7 December 2026. Treasury will set an effective date in a final rule. The existing programme rules, in force since 2 January 2025, stay in place until then.
Which activities would the COINS Act biotech rule prohibit?
Under the Act, deals in notifiable technologies may proceed if reported to Treasury. Deals in prohibited technologies may not. Treasury’s fact sheet describes biotechnology only as a new prohibition, with no notification tier.
Section 851.226(r) covers the “development, engineering, or use of a biological system.” The system must modify, enhance, produce or control listed items. Those items include export-controlled agents and toxins, energetic materials and novel functional materials. They also include pharmaceutical compounds and their delivery systems, plus biofuels. Examples given for pharmaceutical compounds include small molecules, vaccines, blood components and gene therapies.
The proposal also covers brain-computer interfaces and biomanufacturing equipment. Related technology includes biological sequencing, certain flow cytometers and cell sorters, and certain mass spectrometry instruments. Bioinformatics tools and laboratory automation are also listed.
Treasury asks whether “pharmaceutical compounds” should be limited to advanced or frontier technologies. It also asks whether biofuels should exclude fuels such as ethanol. The answers will shape how far the COINS Act biotech provisions reach.
Obligations fall on US persons, including their controlled foreign entities. The proposal names China, including Hong Kong and Macau, as a country of concern. Cuba, Iran, North Korea and Russia are also named. The Act also names Venezuela under the Maduro regime. Treasury’s fact sheet says that regime no longer exists. Venezuela therefore does not currently meet the rule’s definition.
BioPharm International reports that covered entities include those organised under, or majority-owned or controlled from, the named countries.
Does the COINS Act biotech rule cover China licensing deals?
On the proposal as drafted, a pure licence appears to fall outside it. The answer turns on how the rule defines a covered transaction. That definition could still change before the final rule.
What the proposed text lists
Section 851.209 of the proposed rule defines a covered national security transaction. It includes acquiring equity in a covered foreign person and certain loans. It also includes entering a joint venture with a person from a country of concern. The US person must know the venture will engage in a prohibited or notifiable technology.
BioPharm International lists covered transactions as equity investments, convertible debt, joint ventures, greenfield investments and certain limited partner investments. Neither description names a standalone licence.
Section 851.501 lists excepted transactions. These include a transaction “secondary to a covered national security transaction,” including “certain contractual arrangements.” That wording is not a general exemption for licences. It applies only to transactions secondary to a covered one.
Treasury’s FAQs confirm that this contractual exception does not extend to technology or technical knowledge transfer arrangements.
Fierce Biotech reported on 22 October that the proposal largely spares China licensing deals. It said traditional asset licences, paid through cash, milestones and royalties, fall outside covered transactions. It flagged joint ventures as a notable area of risk.
Law firm Morgan Lewis reached a similar view. It said upfront fees, milestones and royalties alone would not make a licence a covered investment.
Where licence-linked exposure may sit
Laurie Burlingame of law firm Morse, Barnes-Brown & Pendleton spoke to Fierce Biotech in May, before the proposal appeared. She did not think “a pure license” without “an equity component or an option” would “necessarily be covered.”
She said NewCo structures may be particularly vulnerable. Chinese licensors in these deals usually take stakes below 20 per cent, Fierce Biotech reported. It described joint ventures as a core covered category under the Act.
Brian Curran of Hogan Lovells said in May that an outright ban on all licensing “seems low” in likelihood.
The proposed rule does not define a joint venture. Treasury uses the plain meaning instead. Two parties contribute capital or assets and share profits and losses. No new entity is needed.
Morgan Lewis notes that licensed technology and development capital shared under profit and loss arrangements may form a joint venture. That can apply even in a US NewCo.
The fact sheet also covers contingent equity interests. A licence that carries an equity stake, an option or shared profits could therefore need review. That is an inference from the definitions, not a Treasury statement.
Why did Congress push for COINS Act biotech coverage?
Pressure built through 2026. Representative Brian Mast chairs the House Foreign Affairs Committee. He urged Bessent in a February letter to add biotech. Fierce Biotech reported that Representative John Moolenaar, who chairs the House select committee on China, wrote separately in May.
Moolenaar asked Treasury to consider “the licensing of pharmaceutical IP” among other areas. That request goes further than the proposal, which does not name licensing.
Congress has a second route. In June, Moolenaar and Representative Debbie Dingell introduced the Biotech Investment National Security Act, known as BINSA. Senators Pete Ricketts and Elissa Slotkin sponsor it in the Senate. The bills, H.R. 9102 and S. 5316, would add licensing of prohibited technology as a covered transaction. Neither has been enacted, Morgan Lewis noted in October.
Reuters reported in September that Treasury was drafting rules to allow most licensing deals. It cited three people briefed on the process. The proposal, published later, is the better evidence.
What is still unsettled?
Three points remain open. First, the COINS Act biotech text may change after comments close on 7 December 2026. Second, Treasury has not set an effective date. The Act requires final regulations by 13 March 2027, which is 450 days after enactment. That deadline is not an effective date, Morgan Lewis notes.
Third, the treatment of existing deals is unsettled. Law firm Freshfields wrote in June that pre-existing deals appear likely to be grandfathered. That view predates the proposal.
The proposal was published in the Federal Register on 26 October 2026, at 91 FR 67396. The docket number is TREAS-DO-2026-0595.
Industry will use the comment period. Kendalle Burlin O’Connell is CEO and President of MassBio. She said “international partnerships and licensing agreements can bring promising scientific discoveries.” MassBio told BioPharm International that it is reviewing the rules and plans to comment.
Early positions are already public. The Council for Innovation Promotion urged Treasury to reconsider, citing risks to licensing discoveries made abroad. BioPharm International reported that the National Security Commission on Emerging Biotechnology backs the move.
Why does the answer matter for deal makers?
China-origin assets are central to Western pipelines. A China out-licensing tracker on this site cites VBInsight data. It counted 85 outbound deals worth $100.4bn in the first half of 2026.
Deals have continued since that data closed. On 19 October 2026, Roche and Hansoh announced a new agreement. Roche pays $400 million upfront and $110 million on the first anniversary. The Roche Hansoh ADC deal terms analysis sets this out. That analysis did not report an equity component.
Coverage under the COINS Act biotech rule turns on structure rather than deal size, lawyers say. A buyer with only a licence has a different position from one that takes equity or forms a venture.
What to watch next
The next test is the comment record. Letters filed by 7 December 2026 will show how pharma, biotech and investors read the draft. The final rule will then show whether licences, options and NewCo structures are in or out.
Until then, the COINS Act biotech rule answers the licensing question only in part. Equity, options and joint ventures are the areas to watch. A pure licence appears to sit outside the proposal, but no final text yet confirms that.














